Imatinib Eg Stada (Imatinib)

Imatinib is a tyrosine kinase inhibitor used in hematologic and solid tumor indications.

• Chronic Myeloid Leukemia (CML): reduces disease progression and improves survival.
• Gastrointestinal Stromal Tumor (GIST): inhibits tumor growth and prolongs progression‑free survival.
• Philadelphia‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): contributes to remission induction and maintenance therapy.

• Imatinib selectively inhibits the BCR‑ABL tyrosine kinase produced by the Philadelphia chromosome translocation, as well as c‑KIT and PDGFR kinases. By blocking ATP binding to these enzymes, it prevents downstream signaling that drives proliferation and survival of malignant cells, leading to cell cycle arrest and apoptosis in susceptible tumors. The inhibition is dose‑dependent and results in reduced phosphorylation of substrates involved in oncogenic pathways, thereby restoring normal cellular regulation.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Edema: swelling of hands, feet, or periorbital area.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Severe neutropenia: marked reduction in white blood cells.
• Cardiac failure: signs of reduced heart function.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Imatinib, clinicians should consider several safety and handling precautions.

• Monitor blood counts: regular CBC to detect cytopenias.
• Assess liver function: periodic LFTs for hepatotoxicity.
• Evaluate cardiac status: baseline and periodic ECG in patients with cardiac risk.
• Use caution in renal impairment: dose adjustment may be required.
• Avoid in patients with known hypersensitivity to imatinib or its excipients.
• Store at ambient temperature: keep below 25 °C, in original container, protect from moisture.

Imatinib interacts with several medicines that can alter its effectiveness or increase toxicity.

Major Interactions (Avoid)

• CYP3A4 strong inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma levels.
• CYP3A4 strong inducers (e.g., rifampicin, carbamazepine): may reduce imatinib exposure.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors: may affect absorption, monitor therapeutic response.
• Antacids containing aluminum or magnesium: separate dosing by at least 2 hours.
• Warfarin: may enhance anticoagulant effect, monitor INR.
• Live attenuated vaccines: potential reduced efficacy, assess risk.